Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.33 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4452078 | 1.00 | SLC1A3 (0.43) | SLC1A3SLC1A2SLC1A1GRIK1SLC7A5 | |
| SCHEMBL2035310 | 0.93 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1GRIK1SLC7A5 | |
| SCHEMBL6871010 | 0.93 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1GRIK1SLC7A5 | |
| SCHEMBL2031192 | 0.93 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1GRIK1SLC7A5 | |
| SCHEMBL2031190 | 0.93 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1GRIK1SLC7A5 | |
| SCHEMBL8101229 | 0.93 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1GRIK1SLC7A5 | |
| SCHEMBL8096822 | 0.93 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1GRIK1SLC7A5 | |
| SCHEMBL2035309 | 0.93 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1GRIK1SLC7A5 | |
| SCHEMBL9575679 | 0.84 | GRIK1 (0.47) | SLC1A3SLC1A2SLC1A1GRIK1TDP1 | |
| SCHEMBL9575678 | 0.84 | GRIK1 (0.47) | SLC1A3SLC1A2SLC1A1GRIK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595299-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595299-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595299-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1303487-A4 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORP (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20050176648-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING-PLOUGH CORPORATION (US) | 2005-08-11 | — | — | US | disclosed |
| EP-1303487-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | Schering Corporation (US) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002008187-A9 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORP (US) | 2003-01-03 | — | — | WO | disclosed |
| US-20020160962-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | MERCK SHARP & DOHME LLC | 2002-10-31 | — | — | US | disclosed |
| WO-2002008187-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2002-01-31 | — | — | WO | disclosed |
| EP-0258183-B1 | PROCESS FOR THE PREPARATION OF 5-AMINO-4-HYDROXYVALERIC-ACID DERIVATIVES | CIBA-GEIGY AG (CH) | 1993-03-17 | — | — | EP | disclosed |
| US-5010189-A | Processes for the preparation of 5-amino-4-hydroxy-valeric acid derivatives | CIBA-GEIGY CORPORATION (US) | 1991-04-23 | — | — | US | disclosed |
| US-4898977-A | Processes for the preparation of 5-amino-4-hydroxyvaleric acid derivatives | CIBA-GEIGY CORPORATION (US) | 1990-02-06 | — | — | US | disclosed |
| EP-0258183-A2 | Process for the preparation of 5-amino-4-hydroxyvaleric-acid derivatives | CIBA-GEIGY AG (CH) | 1988-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160962-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | VIP, HPN, HAVCR2 | SLC1A3 4236/4885SLC1A2 4762/4885SLC1A1 4367/4885 |
| US-20050176648-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | VIP, HPN, HAVCR2 | SLC1A3 4236/4885SLC1A2 4762/4885SLC1A1 4367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.